

Title (en)
DIAGNOSTIC AND THERAPEUTIC METHODS AND AGENTS

Title (de)
DIAGNOSE- UND THERAPIEVERFAHREN UND -MITTEL

Title (fr)
MÉTHODES ET AGENTS DIAGNOSTIQUES ET THÉRAPEUTIQUES

Publication
EP 1951914 A4 20091104 (EN)

Application
EP 06837256 A 20061109

Priority
• US 2006043665 W 20061109
• US 73548005 P 20051109

Abstract (en)
[origin: WO2007056527A2] The present invention relates generally to the fields of therapy and diagnosis of Hepatitis B virus (HBV) infection in animal species including humans. The present invention further provides compounds and compositions useful in the treatment of HBV infection in animal species such as humans including agents which facilitate clearance of HBV and in particular chronic HBV infection.

IPC 8 full level
C12Q 1/70 (2006.01); **C12Q 1/68** (2006.01)

CPC (source: EP)
C12Q 1/6883 (2013.01); **C12Q 1/6886** (2013.01); **C12Q 1/706** (2013.01); **G01N 33/5761** (2013.01); **C12Q 2600/106** (2013.01); **C12Q 2600/136** (2013.01); **G01N 2333/705** (2013.01); **G01N 2800/52** (2013.01)

Citation (search report)
• [X] WO 03043572 A2 20030530 - 3M INNOVATIVE PROPERTIES CO [US]
• [X] WO 2005025583 A2 20050324 - ANADYS PHARMACEUTICALS INC [US], et al
• [X] WO 2005020912 A2 20050310 - 3M INNOVATIVE PROPERTIES CO [US], et al
• [X] HUI CHEE-KIN ET AL: "Upregulation of toll-like receptor 7 is essential for serological clearance of hepatitis B surface antigen in chronic hepatitis B virus (HBV) infection", HEPATOLOGY, vol. 42, no. 4, Suppl. 1, October 2005 (2005-10-01), 56TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-THE-STUDY-OF-LIVE R-DISEASES; SAN FRANCISCO, CA, USA; NOVEMBER 11 -15, 2005, pages 707A - 708A, XP002547237, ISSN: 0270-9139
• [X] ISOGAWA MASANORI ET AL: "Toll-like receptor signaling inhibits hepatitis B virus replication in vivo.", JOURNAL OF VIROLOGY JUN 2005, vol. 79, no. 11, June 2005 (2005-06-01), pages 7269 - 7272, XP002547238, ISSN: 0022-538X
• [A] LEE ET AL: "Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 100, no. 11, 27 May 2003 (2003-05-27), pages 6646 - 6651, XP002307483, ISSN: 0027-8424
• [A] HEMMI H ET AL: "SMALL ANTI-VIRAL COMPOUNDS ACTIVATE IMMUNE CELLS VIA THE TLR7 MYD88-DEPENDENT SIGNALING PATHWAY", NATURE IMMUNOLOGY, NATURE PUBLISHING GROUP, GB, vol. 3, no. 2, 1 February 2002 (2002-02-01), pages 196 - 200, XP009000917, ISSN: 1529-2908
• [A] DAVIES S L ET AL: "Isatoribine - Anti-hepatitis C virus drug TLR7 receptor agonist", DRUGS OF THE FUTURE, vol. 30, no. 9, September 2005 (2005-09-01), pages 886 - 891, XP002547239, ISSN: 0377-8282
• [A] HORMANS YVES ET AL: "Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection", HEPATOLOGY, vol. 42, no. 3, September 2005 (2005-09-01), pages 724 - 731, XP002547240, ISSN: 0270-9139
• See references of WO 2007056527A2

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2007056527 A2 20070518; WO 2007056527 A3 20090514; AU 2006311462 A1 20070518; EP 1951914 A2 20080806; EP 1951914 A4 20091104

DOCDB simple family (application)
US 2006043665 W 20061109; AU 2006311462 A 20061109; EP 06837256 A 20061109